ROMK-IN-32 

ROMK-IN-32 is a renal outer medullary potassium channel (ROMK) inhibitor with an IC₅₀ of 35 nM. ROMK-IN-32 also inhibits hERG with an IC₅₀ of 22 μM^[1].

ROMK-IN-32 (compound 32) exhibits weak human SERT activity (IC₅₀ 10.4 μM; hSERT/hROMK EP=612x)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ROMK-IN-32 demonstrates blood pressure lowering effects in the spontaneously hypertensive rat model^[1].
ROMK-IN-32 exhibits moderate oral bioavailability (78%) following oral administration (1 mg/kg) in WH rats^[1].
ROMK-IN-32 exhibits terminal elimination half-lives (rat 4.7 and dog 5.8 h) due to high plasma clearance (9.6 and 18.3 mL/min/kg respectively) combined with large volumes of distribution (3.0 and 5.0 L/kg respectively) following intravenous administration (rat 0.5 and dog 1.0 mg/kg)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

452.50

C₂₄H₂₈N₄O₅

1914944-54-9

O=C1N(C(C=C2)=NN(C)C2=O)CCC13CCN(C[C@@H](C4=C(C)C5=C(C(OC5)=O)C=C4)O)CC3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shuzhi Dong, et al. Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores. Bioorg Med Chem Lett. 2017 Jun 1;27(11):2559-2566.  [Content Brief]